Out-Licensing
In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- May 21, 2019 Next generation miR-29 mimics as a therapy for pulmonary fibrosis 2019 American Thoracic Society International Conference
- April 29, 2019 The miR-29b mimic remlarsen inhibits fibrosis of a corneal ulcer by preventing EMT and reducing profibrotic gene expression Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- April 26, 2019 MRG106-11-101 A Phase I Clinical Trial of Cobomarsen in Patients with ATLL 19th International Congress HTLV 2019
- March 10, 2019 The miR-29b Mimic Remlarsen as an Anti-Fibrotic Therapeutic in the Eye Association for Ocular Pharmacology and Therapeutics
- January 10, 2019 Cobomarsen, an emerging potential treatment for patients with miR-155 elevated cancers 11th Annual T-Cell Lymphoma Forum
- January 10, 2019 Phase 1 Trial of Cobomarsen, an Inhibitor of miR-155, in Mycosis Fungoides 11th Annual T-Cell Lymphoma Forum
- January 10, 2019 Phase I Trial of Cobomarsen, a MiR-155 Inhibitor, in HTLV-1 Associated Adult T cell Lymphoma/Leukemia 11th Annual T-Cell Lymphoma Forum
- December 2, 2018 Phase 1 Trial of Cobomarsen, an Inhibitor of miR-155, in Mycosis Fungoides American Society for Hematology Annual Meeting
- October 3, 2018 microRNA-155 inhibitor as a therapeutic for neuroinflammatory and neurodegenerative diseases The 23rd International Annual Congress of the World Muscle Society
- October 1, 2018 Inhibition of corneal fibrosis with a miR-29 mimic Oligonucleotide Therapeutics Society 14th Annual Meeting